TORONTO, ONTARIO--(Marketwire - April 22, 2008) - Attention: Business/Financial Editors
The Medipattern Corporation (TSX VENTURE: MKI), an award-winning developer of computer-aided detection (CAD) medical imaging software designed to aid physicians in making better informed biopsy decisions and to permit a higher standard of care for the millions of patients at risk of cancer, is pleased to announce receipt of State Food and Drug Administration (SFDA) approval in the People's Republic of China for its B-CAD™ product. Beijing Eastwide, Medipattern's reseller in China, was instrumental in submitting B-CAD for SFDA approval and will promote and market B-CAD throughout mainland China.
